Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Oncolytics Biotech ( (ONCY) ) has issued an announcement.
Oncolytics Biotech announced on August 28, 2025, that it will participate in two investor conferences in September. CEO Jared Kelly will engage with institutional investors at the H.C. Wainwright 27th Annual Global Investment Conference and the Lake Street Capital Markets 9th Annual Best Ideas Growth Conference. These events are strategic opportunities for Oncolytics to discuss its progress and future plans, potentially impacting its market positioning and stakeholder engagement.
The most recent analyst rating on (ONCY) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the ONCY Stock Forecast page.
More about Oncolytics Biotech
Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered double-stranded RNA immunotherapeutic agent. The company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors for metastatic pancreatic and breast cancers, both of which have received Fast Track designation from the FDA, as well as other gastrointestinal tumors.
Average Trading Volume: 1,114,698
Technical Sentiment Signal: Buy
Current Market Cap: $104.3M
Learn more about ONCY stock on TipRanks’ Stock Analysis page.